Safety and individual experience aren't the same thing
Após nove meses de investigação, a Agência Europeia de Medicamentos concluiu que a semaglutida — princípio ativo do Ozempic e do Wegovy — não apresenta evidências de associação com pensamentos suicidas. A conclusão, alinhada à dos reguladores americanos, encerra uma fase de incerteza iniciada quando a Islândia sinalizou três casos suspeitos. O episódio lembra que, à medida que milhões adotam novas terapias, a vigilância regulatória não é burocracia, mas uma forma de cuidado coletivo — especialmente quando a história já registrou retiradas dolorosas, como a do Acomplia em 2008.
- A sinalização de três casos na Islândia foi suficiente para acionar uma revisão formal em toda a Europa, revelando o quanto o sistema de farmacovigilância responde a indícios mesmo sem certeza.
- Com milhões de pessoas usando GLP-1 agonistas para perda de peso, qualquer suspeita de risco psiquiátrico carregava o peso de um precedente sombrio — a retirada do Acomplia por associação com suicídio.
- O comitê da EMA examinou dados de ensaios clínicos extensos e registros eletrônicos de saúde sem encontrar conexão causal, e a revisão paralela da liraglutida chegou à mesma conclusão.
- As ações da Novo Nordisk subiram quase 2% com o anúncio, enquanto a empresa reafirmou seu compromisso de monitorar eventos adversos, incluindo alterações de comportamento.
- Médicos como Robert Kushner reconhecem que alguns pacientes relatam mudanças emocionais ao iniciar o medicamento — o que exige avaliação individual, não descarte.
- A agência reguladora britânica ainda conduz sua própria revisão, e o uso real dessas drogas em escala global continua a desdobrar histórias que os ensaios clínicos ainda não alcançam.
A Agência Europeia de Medicamentos dedicou nove meses a investigar se a semaglutida, ingrediente ativo do Ozempic e do Wegovy, poderia provocar pensamentos suicidas. Na sexta-feira, 12 de abril, o veredicto foi divulgado: nenhuma evidência de associação. A conclusão coincide com a dos reguladores americanos.
A investigação foi desencadeada em julho, quando a autoridade de saúde da Islândia identificou três casos de pacientes relatando ideação suicida ou automutilação durante o uso dos medicamentos. O comitê de farmacovigilância da EMA analisou dados de ensaios clínicos realizados nos Estados Unidos e registros eletrônicos de saúde — nenhuma das fontes revelou conexão causal. A liraglutida, outro agonista do receptor GLP-1 vendido como Saxenda, passou pelo mesmo escrutínio e obteve o mesmo resultado.
O contexto histórico tornava a questão especialmente sensível. Em 2008, o Acomplia, medicamento para obesidade da Sanofi, foi retirado do mercado europeu após ser associado a pensamentos suicidas. Essa memória mantém reguladores e médicos em estado de alerta permanente diante de qualquer sinal psiquiátrico em novas terapias para perda de peso.
O professor Robert Kushner, da Northwestern University, acolheu a clareza regulatória, mas ponderou que alguns pacientes relatam alterações emocionais ao iniciar o tratamento — o que merece avaliação médica individualizada. A agência reguladora britânica ainda conduz sua própria revisão. Enquanto isso, o uso em larga escala desses medicamentos continua a se expandir pelo mundo, e o que ainda pode emergir desse experimento coletivo permanece uma questão em aberto.
Europe's medicines regulator spent nine months examining whether semaglutida—the active ingredient in Novo Nordisk's blockbuster diabetes and weight-loss drugs Ozempic and Wegovy—could trigger suicidal thoughts in patients. On Friday, April 12, the European Medicines Agency announced it found no evidence of such a link. The conclusion aligned with what American regulators had already determined.
The investigation began in July after Iceland's health authority flagged three cases of patients reporting suicidal ideation or self-harm while taking these medications. That signal was enough to warrant a formal review. The EMA's pharmacovigilance committee, tasked with monitoring drug safety across the continent, examined data from extensive clinical trials conducted in the United States and analyzed electronic health records. Neither source revealed a causal connection between semaglutida use and increased suicide risk. A parallel review of liraglutida, another GLP-1 receptor agonist sold as Saxenda for weight loss, produced the same finding.
The stakes were significant enough that Novo Nordisk's stock price rose nearly two percent on the announcement. The company responded by reaffirming its commitment to monitoring all adverse event reports, including those involving suicidal behavior. Robert Kushner, a professor at Northwestern University's Feinberg School of Medicine, welcomed the regulatory clarity. He noted that while the thorough review by two major agencies should reassure both patients and prescribing doctors, he acknowledged that some people do report changes in their emotional or mental health after starting the medication—a phenomenon that warrants individual medical evaluation rather than dismissal.
The caution reflects a darker chapter in obesity treatment history. In 2008, the European market withdrew Acomplia, a weight-loss drug manufactured by Sanofi, after it became associated with suicidal thoughts. That episode left regulators and physicians wary. Today, as millions of people worldwide adopt GLP-1 agonists for weight management—drugs originally developed to control blood sugar in diabetics—the medical community remains alert to dangers that might not yet be visible in clinical trial data. Ozempic, Wegovy, and Eli Lilly's competing drug Mounjaro have all shown themselves to be relatively safe in their formal testing, with no suicide risk documented. But the real-world use of these medications is still unfolding.
The UK's Medicines and Healthcare Products Regulatory Agency continues its own review of the suicide question and has said it will communicate any additional guidance to patients and healthcare professionals as warranted. In October, the EMA's pharmacovigilance committee had already cleared GLP-1 agonists of any link to thyroid cancer. The regulatory machinery, it seems, is working as designed—moving deliberately, following signals, and publishing findings that either confirm safety or demand action. For now, the signal about suicide has not held up under scrutiny. What emerges next, as these drugs reach more people, remains to be seen.
Notable Quotes
After a thorough review by two major regulatory agencies, there appears to be no increased risk of suicidal behavior associated with semaglutida use— Robert Kushner, Northwestern University Feinberg School of Medicine
I don't dismiss when people feel a change in their emotional or mental health while taking the medication, but that requires additional medical evaluation— Robert Kushner, Northwestern University Feinberg School of Medicine
The Hearth Conversation Another angle on the story
Why did this investigation take nine months? That seems like a long time for a straightforward safety question.
Because they weren't just looking at clinical trial data—which is controlled and limited. They had to pull together real-world health records from thousands of patients, cross-reference adverse event reports, and rule out confounding factors. A person on semaglutida might have suicidal thoughts for reasons completely unrelated to the drug. Nine months is actually fast for that kind of work.
The Iceland cases—three people reporting suicidal thoughts—that was enough to trigger a continent-wide investigation?
Yes, and that's the system working correctly. You don't need a huge number of cases to warrant scrutiny. Three credible reports of a serious adverse event are a signal. The question becomes: is it real, or is it noise? That's what the nine months answered.
But the company says it will keep monitoring. Does that mean they're not fully confident in this conclusion?
Not necessarily. Novo Nordisk has a legal and ethical obligation to monitor all adverse events indefinitely. That's standard practice. What they're saying is: we accept the regulator's finding, but we're not going to stop watching. It's actually the responsible position.
Why does the history of Acomplia matter here?
Because it's a cautionary tale. Acomplia was approved, then withdrawn when the suicide signal became undeniable. It shows that regulators can miss things, or that things can emerge in real-world use that don't show up in trials. So when doctors see millions of people taking these new drugs, they're rightfully staying alert.
If the drugs are safe, why does Kushner say some people do report emotional changes?
Because safety and individual experience aren't the same thing. A drug can be safe at the population level—no causal link to suicide—and still affect someone's mood or mental state in ways that are real but not systematic. That person needs a doctor's attention, not dismissal. The regulator's job is population-level safety. The doctor's job is individual care.